Published in J Neurosci on March 05, 2008
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci (2011) 1.79
Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol (2012) 1.60
Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta (2008) 1.51
Non-motor features of Parkinson disease. Nat Rev Neurosci (2017) 1.42
Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol (2008) 1.26
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb Perspect Med (2012) 1.08
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain (2013) 1.07
Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr Neurol Neurosci Rep (2008) 1.06
A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun (2010) 1.05
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (2014) 1.03
Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus. J Neurosci (2012) 1.01
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener (2010) 1.00
Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis (2012) 1.00
Neuroregeneration in neurodegenerative disorders. BMC Neurol (2011) 0.98
Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum Mol Genet (2009) 0.97
Adult neurogenesis in neurodegenerative diseases. Cold Spring Harb Perspect Biol (2015) 0.96
Limitations of animal models of Parkinson's disease. Parkinsons Dis (2010) 0.96
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. Hum Mol Genet (2014) 0.94
NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease. J Neurosci (2012) 0.93
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein. Am J Pathol (2013) 0.92
Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci (2012) 0.92
Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors. Gene Ther (2010) 0.92
Evaluation of Models of Parkinson's Disease. Front Neurosci (2016) 0.90
Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases? Biomed Res Int (2014) 0.87
Genetically engineered mouse models of Parkinson's disease. Brain Res Bull (2011) 0.86
Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol Dis (2014) 0.85
Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Neurogenetics (2010) 0.85
Parkinson's disease mouse models in translational research. Mamm Genome (2011) 0.85
Neural stem cells in the adult human brain. Biol Biomed Rep (2012) 0.85
CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clin Exp Immunol (2008) 0.82
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience (2013) 0.82
Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol Dis (2013) 0.81
Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors. PLoS One (2013) 0.81
Nestin-positive/SOX2-negative cells mediate adult neurogenesis of nigral dopaminergic neurons in mice. Neurosci Lett (2016) 0.80
Time course and progression of wild type α-synuclein accumulation in a transgenic mouse model. BMC Neurosci (2013) 0.80
Improved spatial learning and memory by perilla diet is correlated with immunoreactivities to neurofilament and α-synuclein in hilus of dentate gyrus. Proteome Sci (2012) 0.79
Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease. Neurobiol Dis (2015) 0.78
Epigenetic mechanisms in neurogenesis. Nat Rev Neurosci (2016) 0.78
Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity. Neural Plast (2014) 0.77
Toxin-Induced Experimental Models of Learning and Memory Impairment. Int J Mol Sci (2016) 0.76
The temporal expression pattern of alpha-synuclein modulates olfactory neurogenesis in transgenic mice. PLoS One (2015) 0.76
Role of metabotropic glutamate receptors in the regulation of pancreatic functions. Biochem Pharmacol (2013) 0.75
Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo. J Biol Chem (2016) 0.75
The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease. Neuroscience (2015) 0.75
The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease. Neuroscience (2016) 0.75
E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. Proc Natl Acad Sci U S A (2017) 0.75
Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci (2017) 0.75
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet (2012) 8.42
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Transient expression of doublecortin during adult neurogenesis. J Comp Neurol (2003) 5.61
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell (2009) 4.60
Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med (2008) 4.54
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol (2006) 4.32
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol (2010) 3.92
PML in a patient treated with fumaric acid. N Engl J Med (2013) 3.87
Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol (2004) 3.83
Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci (2005) 3.79
Protein abundance profiling of the Escherichia coli cytosol. BMC Genomics (2008) 3.78
Temporal and spatial dynamics of brain structure changes during extensive learning. J Neurosci (2006) 3.65
ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J (2010) 3.58
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45
CORUM: the comprehensive resource of mammalian protein complexes. Nucleic Acids Res (2007) 3.23
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci (2003) 2.93
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. Nat Genet (2002) 2.87
Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet (2010) 2.81
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet (2004) 2.75
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol (2009) 2.68
Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology (2008) 2.65
Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke (2003) 2.63
Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem (2009) 2.60
FUS pathology in basophilic inclusion body disease. Acta Neuropathol (2009) 2.52
Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A (2008) 2.50
Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol (2012) 2.48
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J (2009) 2.37
Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol (2005) 2.36
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
PET/MR images acquired with a compact MR-compatible PET detector in a 7-T magnet. Radiology (2007) 2.36
Repetitive bilateral arm training and motor cortex activation in chronic stroke: a randomized controlled trial. JAMA (2004) 2.36
Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med (2006) 2.33
ProfCom: a web tool for profiling the complex functionality of gene groups identified from high-throughput data. Nucleic Acids Res (2008) 2.33
MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med (2008) 2.30
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol (2013) 2.27
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004) 2.22
Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med (2008) 2.22
PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med (2010) 2.22
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol (2011) 2.17
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol (2004) 2.15
Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet (2012) 2.12
TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol (2007) 2.12
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci (2010) 2.05
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke (2004) 2.04
TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol (2008) 2.02
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. J Neurosurg (2014) 2.02
14-3-3 proteins in the nervous system. Nat Rev Neurosci (2003) 2.02
Long-term survival and cell death of newly generated neurons in the adult rat olfactory bulb. Eur J Neurosci (2002) 1.96
Evaluation of high performance data acquisition boards for simultaneous sampling of fast signals from PET detectors. Phys Med Biol (2005) 1.95
Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys (2011) 1.94
Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseases. Brain (2010) 1.93
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol (2004) 1.89
The PEDANT genome database in 2005. Nucleic Acids Res (2005) 1.88
Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem (2007) 1.87
Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol (2003) 1.85
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med (2005) 1.85
A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain (2007) 1.82
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 1.81
Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol (2008) 1.79
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol (2002) 1.79
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol (2008) 1.78
Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem (2009) 1.76
Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res (2004) 1.76
Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging (2009) 1.74
Short and long-term motor skill learning in an accelerated rotarod training paradigm. Neurobiol Learn Mem (2004) 1.72
Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci (2002) 1.72
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science (2008) 1.67